<DOC>
	<DOCNO>NCT02842294</DOCNO>
	<brief_summary>The primary aim french multicenter national study ass compare time quality life score deterioration ( targeted dimension : global health , fatigue emotional functionning EORTC QLQC30 accord first line chemotherapy associate bevacizumab metastatic colorectal patient .</brief_summary>
	<brief_title>Cohort Study Assess Impact Chemotherapy Plus Bevacizumab Health Related Quality Life First Line Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>age &gt; 18years metastatic colorectal cancer ( non resectable ) 1st chemotherapy include bevacizuman treatment contreindication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>bevacizumab</keyword>
	<keyword>health relate quality life</keyword>
</DOC>